Company
Building with purpose and taking our responsibility seriously
Working with the urgency patients live with
Beren is public benefit corporation building a new model of integrated, patient-aligned biotechnology.
Beren was designed from inception to understand the needs of patient communities, healthcare providers, and health systems in order to identify, develop, and provide access to transformative medicines.
Since our founding six years ago, we have been relentlessly focused on the development of cyclodextrin-based therapeutics for conditions characterized by impaired cholesterol trafficking, including Niemann-Pick disease type C (NPC) and other neurodegenerative conditions.
We've brought together pathbreaking research, clinical, manufacturing, access, and commercial expertise to pursue treatments tackling the root causes underlying disease. Together with the patient community and partners across the ecosystem, we are driving forward innovation that can accelerate our mission and build better medicines for patients.
Through our subsidiary Mandos LLC, we are committed to the development of adrabetadex* for individuals living with NPC, an ultra-rare genetic disease that affects the body’s ability to metabolize cholesterol within cells that affects the brain and other organ systems.
Our Public Benefit Purpose
Built for lasting impact
All people living with a disease — and the caregivers, clinicians, and health systems that support them — need a biotechnology company that integrates their needs from the beginning of the drug discovery process to repeatedly and consistently deliver meaningful therapies.
Beren's public benefit purpose is to discover, develop, and deliver novel pharmaceutical therapies that provide optimal benefit for patients.
Our team
Leadership for the long term
We've built a team of passionate, proven leaders bringing together their experiences in high growth companies across drug discovery, development, and commercialization to serve our patients.
